CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
March 04, 2021 |
$0 |
ADDITIONAL FUNDING TO COMPLETE WORK AND EXTEND THE POP END DATE TO 07/01/2021. |
Modal: Rail Transportation Applied Research/Exploratory Development R&D |
Federal Railroad Administration |
February 26, 2021 |
$40,840 |
CLINICAL SAMPLE TESTING FOR SARS-COV-2 VACCINE CANDIDATES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
February 10, 2021 |
$0 |
THE PURPOSE OF THIS MODIFICATION IS TO INCORPORATE A NO ADDITIONAL COST EXTENSION TO OPTIONS 1 AND 3C. |
Biomedical R&D |
National Institutes of Health |
February 08, 2021 |
$0 |
BATTELLE ANIMAL MODELS |
Biomedical R&D |
Office of Assistant Secretary for Preparedness and Response - HHS |
January 29, 2021 |
$3,713,964 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
January 22, 2021 |
$777,104 |
THIS IS A CONTRACT BETWEEN THE DEPARTMENT OF HEALTH AND HUMAN SERVICES / THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE (HHS/ASPR) AND BATTELLE MEMORIAL INSTITUTE FOR BATTELLE SUPPORT TO RECOVERY, STAGING, REDEPLOYMENT AND DISPOSAL OPERATIONS |
Logistics Support Services |
Office of Assistant Secretary for Preparedness and Response - HHS |
January 14, 2021 |
$6,886,188 |
4610055864!OPERATIONAL EQUIPMENT IST - |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
January 12, 2021 |
$0 |
8507317119!1.0 PROGRAM MGMT, 2.0 STAFFIN |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
December 03, 2020 |
-$11,569,588 |
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
December 02, 2020 |
$1,064,710 |
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
November 10, 2020 |
$0 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
November 10, 2020 |
$252,370 |
COVID-19 FFRS |
Laboratory Testing |
Centers for Disease Control and Prevention |
October 29, 2020 |
$0 |
POP EXTENSION - DELAYS DUE TO COVID-19. |
Modal: Rail Transportation Applied Research/Exploratory Development R&D |
Federal Railroad Administration |
September 25, 2020 |
$0 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
September 23, 2020 |
$0 |
CLINICAL AND NHP SAMPLE TESTING FOR SARS-COV-2 VACCINE AND OTHER BIOLOGICAL PRODUCT CANDIDATES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
September 18, 2020 |
$98,800 |
EXERCISE OPTION 3B - COVID-19 PROJECT |
Biomedical R&D |
National Institutes of Health |
September 17, 2020 |
$1,090,940 |
DECON OF N95 MASKS |
Other Salvage |
Department of Veterans Affairs |
September 16, 2020 |
-$999,999 |
8507317119!1.0 PROGRAM MGMT, 2.0 STAFFIN |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
September 08, 2020 |
$2,100,000 |
8507310584!CCDS OPERATIONS SEPTEMBER |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
September 08, 2020 |
$28,500,000 |
"THE PERSISTENCE OF AEROSOLIZED SARS-COV-2 ON THE SURFACES OF FFRS" |
Other Professional Services |
Centers for Disease Control and Prevention |
August 26, 2020 |
$258,945 |
TASK AREA 5: PREPAREDNESS FOR TESTING NIAID PRIORITY VACCINES IN GENERAL SAFETY AND TOXICOLOGY STUDIES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
August 26, 2020 |
$814,926 |
CLINICAL AND NHP SAMPLE TESTING FOR SARS-COV-2 VACCINE AND OTHER BIOLOGICAL PRODUCT CANDIDATES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
August 21, 2020 |
$1,005,452 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
August 13, 2020 |
$1,457,965 |
MODIFICATION IS TO EXERCISE QUANTITY OPTION 2 IN THE AMOUNT OF $1,746,570 AND CHANGE THE TASK ORDER COMPLETION PERIOD FROM JANUARY 26, 2021 TO MARCH 20, 2021. |
Biomedical R&D |
National Institutes of Health |
August 12, 2020 |
$1,746,570 |
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
Biomedical R&D |
National Institutes of Health |
August 04, 2020 |
-$1,090,940 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
July 20, 2020 |
$5,636,058 |
PT |
Combat, Assault and Tactical Vehicles, Wheeled |
Defense Contract Management Agency |
July 16, 2020 |
$0 |
THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO 1) MODIFY THE SCOPE OF TASK 5 OF ATTACHMENT 1 - PERFORMANCE WORK STATEMENT(PWS) TO INCORPORATE A VIRTUAL MEETING INSTEAD OF AN IN-PERSON MEETING DUE TO TRAVEL RESTRICTIONS IMPOSED BY THE CURRENT PANDEM |
Program Management/Support Services |
Federal Highway Administration |
July 15, 2020 |
$0 |
DISINFECTION APPROACHES TO REMEDIATE CORONAVIRUS-CONTAMINATED SURFACES AND MATERIALS. (COVID-19) |
Engineering/Technical Services |
Environmental Protection Agency |
June 29, 2020 |
$322,566 |
NEW STREAMS III TASK ORDER:TITLED METHODS TO REDUCE THE RISKS FROM ENVIRONMENTAL TRANSMISSION OF CORONAVIRUS VIA CONTAMINATED SURFACES OR MATERIALS.(COVID-19) |
Engineering/Technical Services |
Environmental Protection Agency |
June 24, 2020 |
$222,362 |
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
June 10, 2020 |
$0 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
May 28, 2020 |
$695,714 |
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
Biomedical R&D |
National Institutes of Health |
May 27, 2020 |
$1,088,087 |
8507310459!1.0 PROGRAM MANAGEMENT |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
May 22, 2020 |
-$3,750,000 |
DISINFECTION APPROACHES TO REMEDIATE CORONAVIRUS-CONTAMINATED SURFACES AND MATERIALS. (COVID-19) |
Engineering/Technical Services |
Environmental Protection Agency |
May 22, 2020 |
$474,648 |
8507310584!CCDS OPERATION JUNE |
Medical and Surgical Instruments, Equipment and Supplies |
Defense Logistics Agency |
May 21, 2020 |
-$100,592,000 |
SEROLOGY SURGE TESTING BPA |
Laboratory Testing |
Centers for Disease Control and Prevention |
May 14, 2020 |
$0 |
SEROLOGY SURGE TESTING BPA |
Laboratory Testing |
Centers for Disease Control and Prevention |
May 07, 2020 |
$2,500 |
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
Biomedical R&D |
National Institutes of Health |
May 06, 2020 |
$1,090,940 |
(COVID-19) NEW STREAMS III TO TITLED:EFFICACY ASSESSMENT OF SURFACE-APPLIED MICROBIOSTATS TO REDUCE ENVIRONMENTAL EXPOSURE TO VIRUSES. |
Engineering/Technical Services |
Environmental Protection Agency |
May 02, 2020 |
$558,020 |
NEW STREAMS III TASK ORDER:TITLED METHODS TO REDUCE THE RISKS FROM ENVIRONMENTAL TRANSMISSION OF CORONAVIRUS VIA CONTAMINATED SURFACES OR MATERIALS.(COVID-19) |
Engineering/Technical Services |
Environmental Protection Agency |
April 30, 2020 |
$1,499,256 |
IMMUNOGENICITY AND EFFICACY TESTING OF MEDICAL COUNTERMEASURES (VACCINES AND OTHER BIOLOGICS) AGAINST EMERGING INFECTIOUS DISEASES INCLUDING COVID-19 (SARS-C0V2) |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
April 21, 2020 |
$2,429,847 |
DEVELOPMENT OF ASSAYS AND REAGENTS FOR CORONAVIRUS VACCINES |
Biomedical Applied Research/Exploratory Development R&D |
National Institutes of Health |
April 21, 2020 |
$2,254,547 |
COVID-19 FFRS |
Laboratory Testing |
Centers for Disease Control and Prevention |
April 15, 2020 |
$240,000 |
DECON OF N95 MASKS |
Other Salvage |
Department of Veterans Affairs |
April 03, 2020 |
$999,999 |
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
Biomedical R&D |
National Institutes of Health |
April 02, 2020 |
$1,094,669 |
DEVELOPMENT OF ANIMAL MODELS FOR EVALUATION OF MEDICAL COUNTERMEASURES FOR SARS-COV-2 |
Biomedical Advanced Development R&D |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 30, 2020 |
$9,132,334 |
DEVELOPMENT OF ANIMAL MODELS FOR EVALUATION OF MEDICAL COUNTERMEASURES FOR SARS-COV-2 |
Biomedical Advanced Development R&D |
Office of Assistant Secretary for Preparedness and Response - HHS |
March 28, 2020 |
$698,638 |
PCMID: DEVELOPMENT AND USE OF A NON-HUMAN PRIMATE MODEL OF SARS-COV-2 INFECTION |
Biomedical R&D |
National Institutes of Health |
March 27, 2020 |
$892,089 |